Ensuring trial validity by data quality assurance and diversification of monitoring methods
暂无分享,去创建一个
Douglas G Altman | Marc Buyse | Frank E Harrell | Colin Baigent | Jonathan R Emberson | F. Harrell | M. Buyse | D. Altman | J. Emberson | C. Baigent
[1] Stephen Evans,et al. Are these data real? Statistical methods for the detection of data fabrication in clinical trials , 2005, BMJ : British Medical Journal.
[2] Sydes,et al. A proposed charter for clinical trial data monitoring committees: helping them to do their job well , 2005, The Lancet.
[3] Jonathan A C Sterne,et al. Sifting the evidence—what's wrong with significance tests? , 2001, BMJ : British Medical Journal.
[4] P. Lachenbruch,et al. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. , 1999, Statistics in medicine.
[5] M. Laakso,et al. The European Stroke Prevention Study , 1991, Neurology.
[6] David L. DeMets,et al. Data Monitoring Committees in Clinical Trials: A Practical Perspective , 2002 .
[7] D G Altman,et al. Absence of evidence is not evidence of absence. , 1996, Australian veterinary journal.
[8] D. Spiegelhalter,et al. Issues in data monitoring and interim analysis of trials. , 2005, Health technology assessment.
[9] J. Abraham. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .
[10] Peter Sleight,et al. Data-monitoring committees in clinical trials , 1993, The Lancet.